FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922976514> ?p ?o ?g. }

• W2922976514 abstract "The elevated calcium and phosphorus levels in patients undergoing hemodialysis may increase the risk of all-cause mortality. Paricalcitol, as a new vitamin D receptor activator (VDRA), seemed to be effective in reducing the calcium and phosphorus levels.The aim of this study was to compare the efficacy and safety of paricalcitol with other VDRAs in patients undergoing hemodialysis.PubMed, Embase, and Web of Science database were systematically reviewed.Studies that focused on the use of paricalcitol for hemodialysis patients were eligible for inclusion.Two independent investigators performed the literature search, data extraction, and assessment of methodological quality. The outcomes were expressed with standard mean difference (SMD), HR, or risk ratio (RR) with 95% CI.Thirteen studies involving 112,695 patients were included in this meta-analysis. Among these studies, four studies were cohort studies and nine studies were randomized controlled trials (RCTs). For cohort studies, they were regarded as being of high quality; for RCTs, only one was classified as being at low risk of bias; and the remaining eight studies were at being unclear risk of bias. Compared with other VDRAs, paricalcitol significantly improved the overall survival (HR =0.86, 95% CI: 0.80, 0.92; P<0.001) and reduced the intact parathyroid hormone (iPTH) (SMD =-0.53, 95% CI: -0.90, -0.17; P=0.004). Paricalcitol offered similar effect with other VDRAs in the control of calcium (SMD =0.32, 95% CI: -0.04, 0.67; P=0.078) and phosphorus (SMD =0.06, 95% CI: -0.26, 0.37; P=0.727) levels. However, the serum change in calcium phosphate product was greater in the paricalcitol group than in the other VDRA group (SMD =2.13, 95% CI: 0.19, 4.07; P=0.031). There was no significant difference in the incidence of adverse events between the two groups (RR =1.02, 95% CI: 0.93, 1.12; P=0.674).Paricalcitol was crucial in reducing the mortality in patients undergoing hemodialysis. Moreover, both paricalcitol and other VDRAs were effective in control of the serum iPTH, calcium, and phosphorus levels. Given the potential limitations in this study, more prospective large-scale, well-conducted RCTs are needed to confirm these findings." @default.
• W2922976514 created "2019-04-01" @default.
• W2922976514 creator A5034218699 @default.
• W2922976514 creator A5034943324 @default.
• W2922976514 creator A5067779080 @default.
• W2922976514 creator A5074172860 @default.
• W2922976514 creator A5081413016 @default.
• W2922976514 creator A5086124785 @default.
• W2922976514 date "2019-03-01" @default.
• W2922976514 modified "2023-09-24" @default.
• W2922976514 title "<p>Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis</p>" @default.
• W2922976514 cites W1592218887 @default.
• W2922976514 cites W1835676912 @default.
• W2922976514 cites W1912925321 @default.
• W2922976514 cites W1964435302 @default.
• W2922976514 cites W1967330581 @default.
• W2922976514 cites W1979268971 @default.
• W2922976514 cites W1985834097 @default.
• W2922976514 cites W2009730157 @default.
• W2922976514 cites W2013997927 @default.
• W2922976514 cites W2021514219 @default.
• W2922976514 cites W2025589168 @default.
• W2922976514 cites W2035221187 @default.
• W2922976514 cites W2038986027 @default.
• W2922976514 cites W2055220862 @default.
• W2922976514 cites W2074826032 @default.
• W2922976514 cites W2081385953 @default.
• W2922976514 cites W2082042666 @default.
• W2922976514 cites W2087806333 @default.
• W2922976514 cites W2095527531 @default.
• W2922976514 cites W2098923148 @default.
• W2922976514 cites W2105407962 @default.
• W2922976514 cites W2105417592 @default.
• W2922976514 cites W2107207648 @default.
• W2922976514 cites W2107328434 @default.
• W2922976514 cites W2114902110 @default.
• W2922976514 cites W2116618632 @default.
• W2922976514 cites W2117334533 @default.
• W2922976514 cites W2125435699 @default.
• W2922976514 cites W2127561755 @default.
• W2922976514 cites W2128372431 @default.
• W2922976514 cites W2133560366 @default.
• W2922976514 cites W2136486000 @default.
• W2922976514 cites W2143470199 @default.
• W2922976514 cites W2150000105 @default.
• W2922976514 cites W2156098321 @default.
• W2922976514 cites W2157823046 @default.
• W2922976514 cites W2315590268 @default.
• W2922976514 cites W2328615536 @default.
• W2922976514 cites W2333333141 @default.
• W2922976514 cites W2425433868 @default.
• W2922976514 cites W2534792730 @default.
• W2922976514 cites W2588681363 @default.
• W2922976514 cites W2786724349 @default.
• W2922976514 cites W2991792334 @default.
• W2922976514 cites W4211046201 @default.
• W2922976514 cites W62536823 @default.
• W2922976514 doi "https://doi.org/10.2147/dddt.s176257" @default.
• W2922976514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6445244" @default.
• W2922976514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30992658" @default.
• W2922976514 hasPublicationYear "2019" @default.
• W2922976514 type Work @default.
• W2922976514 sameAs 2922976514 @default.
• W2922976514 citedByCount "3" @default.
• W2922976514 countsByYear W29229765142020 @default.
• W2922976514 countsByYear W29229765142021 @default.
• W2922976514 countsByYear W29229765142022 @default.
• W2922976514 crossrefType "journal-article" @default.
• W2922976514 hasAuthorship W2922976514A5034218699 @default.
• W2922976514 hasAuthorship W2922976514A5034943324 @default.
• W2922976514 hasAuthorship W2922976514A5067779080 @default.
• W2922976514 hasAuthorship W2922976514A5074172860 @default.
• W2922976514 hasAuthorship W2922976514A5081413016 @default.
• W2922976514 hasAuthorship W2922976514A5086124785 @default.
• W2922976514 hasBestOaLocation W29229765141 @default.
• W2922976514 hasConcept C124490489 @default.
• W2922976514 hasConcept C126322002 @default.
• W2922976514 hasConcept C168563851 @default.
• W2922976514 hasConcept C201903717 @default.
• W2922976514 hasConcept C2776478404 @default.
• W2922976514 hasConcept C2778063415 @default.
• W2922976514 hasConcept C2778838027 @default.
• W2922976514 hasConcept C2779524405 @default.
• W2922976514 hasConcept C2781208988 @default.
• W2922976514 hasConcept C519063684 @default.
• W2922976514 hasConcept C71924100 @default.
• W2922976514 hasConcept C95190672 @default.
• W2922976514 hasConceptScore W2922976514C124490489 @default.
• W2922976514 hasConceptScore W2922976514C126322002 @default.
• W2922976514 hasConceptScore W2922976514C168563851 @default.
• W2922976514 hasConceptScore W2922976514C201903717 @default.
• W2922976514 hasConceptScore W2922976514C2776478404 @default.
• W2922976514 hasConceptScore W2922976514C2778063415 @default.
• W2922976514 hasConceptScore W2922976514C2778838027 @default.
• W2922976514 hasConceptScore W2922976514C2779524405 @default.
• W2922976514 hasConceptScore W2922976514C2781208988 @default.
• W2922976514 hasConceptScore W2922976514C519063684 @default.
• W2922976514 hasConceptScore W2922976514C71924100 @default.
• W2922976514 hasConceptScore W2922976514C95190672 @default.
• W2922976514 hasLocation W29229765141 @default.

• next